Role of Urinary Sphingosine 1-Phosphate as a Biomarker for Detrusor Hyperactivity in Multiple Sclerosis (SEP-1)

Toulouse University Hospital

Status: Enrolling

Conditions: Multiple Sclerosis

Treatments: Other: S1P level

Study type: Observational

Funder types: Other

Identifiers

NCT06161376

RC31/23/0346

Details and patient eligibility

About

This study aims to establish a link between urinary Sphingosine 1-Phosphate (S1P) levels and detrusor activity in multiple sclerosis (MS) patients. MS often involves urological symptoms, primarily overactive bladder. The gold standard for evaluation and treatment monitoring is invasive urodynamic testing. Preliminary research at Toulouse University Hospital suggests urinary S1P levels may be a potential biomarker for detrusor activity in MS. This study aims to confirm this potential biomarker's utility.

Enrollment: 400 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• French residents enrolled in the social security system
• Patients diagnosed with multiple sclerosis (according to McDonald 2017 criteria), whether receiving treatment or not
• Patients scheduled for urodynamic assessment as part of their management

Exclusion criteria

• Pregnant or lactating females
• Patients under legal guardianship
• Untreated urinary tract infection at the time of inclusion
• Known anatomical subvesical obstruction Known pelvic floor disorder Urothelial carcinoma Interstitial cystitis Augmentation cystoplasty

Trial design

400 participants in 1 patient group

multiple sclerosis

Description:

Patients diagnosed with MS requiring urodynamic assessment will be recruited during outpatient visits at Toulouse University Hospital. Initial consultations will involve questionnaire completion, 72-hour voiding diaries, and urine sample collection just before urodynamic assessments.

Treatment:

Other: S1P level